Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
Under what circumstances would you consider steroids in Staphylococcus-associated glomerulonephritis with crescents on kidney biopsy?
Related Questions
How would you approach a patient with class III and V lupus nephritis, already on HCQ, MMF, voclosporin and losartan, but has continued proteinuria not yet attaining complete renal response?
How do you counsel patients who are found to have a carrier mutation in a single high-risk APOL1 allele?
How do you address patient concerns regarding the necessity of REMS monitoring when prescribing sparsentan?
How do various therapeutic approaches for IgA nephropathy target the different stages of the four-hit hypothesis?
What is your treatment approach for pregnant patients with IgA nephropathy who have worsening proteinuria during the first trimester?
How do you approach distinguishing between primary and secondary FSGS in a patient who is PLA2R negative?
What is your recommended sequence of therapies for achieving optimal proteinuria reduction in IgA nephropathy, especially in light of the recent approvals of sparsentan, delayed-release budesonide, and iptacopan?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
How does your approach to the differential diagnosis of membranous nephropathy change when PLA2R positivity is detected alongside a chronic viral infection such as HIV, HBV, or HCV?
Under what circumstances would you consider obinutuzumab instead of rituximab when treating primary membranous nephropathy?
